Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session. NEW YORK, Aug. 7, 2026 /PRNewswire/ -- A 22% single-session decline hit Pharming Group (NASDAQ: PHAR) shareholders...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.